Geoffrey Porges
Stock Analyst at Leerink Partners
(1.50)
# 3,562
Out of 5,178 analysts
114
Total ratings
46.05%
Success rate
-1.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Outperform | $36 → $49 | $21.21 | +131.02% | 9 | Mar 2, 2026 | |
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $27.57 | +103.12% | 10 | Dec 15, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $756.73 | +12.33% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $63.29 | -24.16% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $353.16 | -38.84% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $211.12 | -36.06% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $27.35 | -59.78% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $136.88 | -45.21% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $46.62 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $15.19 | -34.17% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $453.74 | -61.43% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $28.87 | +190.96% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $53.94 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $6.20 | +883.87% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $191.06 | - | 8 | Mar 16, 2017 |
Arcus Biosciences
Mar 2, 2026
Maintains: Outperform
Price Target: $36 → $49
Current: $21.21
Upside: +131.02%
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $27.57
Upside: +103.12%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $756.73
Upside: +12.33%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $63.29
Upside: -24.16%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $353.16
Upside: -38.84%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $211.12
Upside: -36.06%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $27.35
Upside: -59.78%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $136.88
Upside: -45.21%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $46.62
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $15.19
Upside: -34.17%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $453.74
Upside: -61.43%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $28.87
Upside: +190.96%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $53.94
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $6.20
Upside: +883.87%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $191.06
Upside: -